APA (7th ed.) Citation

D, D., T, W., K, J., T, K., P, R., A, P., . . . AJ, J. (2026). Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): Primary analysis of a randomised, open-label, phase 3 trial. The Lancet. Haematology, 13(4), e241. https://doi.org/10.1016/S2352-3026(26)00011-6

Chicago Style (17th ed.) Citation

D, Dytfeld, et al. "Carfilzomib, Lenalidomide, and Dexamethasone Compared with Lenalidomide Treatment After Autologous Haematopoietic Stem-cell Transplantation in Patients with Multiple Myeloma (ATLAS): Primary Analysis of a Randomised, Open-label, Phase 3 Trial." The Lancet. Haematology 13, no. 4 (2026): e241. https://doi.org/10.1016/S2352-3026(26)00011-6.

MLA (9th ed.) Citation

D, Dytfeld, et al. "Carfilzomib, Lenalidomide, and Dexamethasone Compared with Lenalidomide Treatment After Autologous Haematopoietic Stem-cell Transplantation in Patients with Multiple Myeloma (ATLAS): Primary Analysis of a Randomised, Open-label, Phase 3 Trial." The Lancet. Haematology, vol. 13, no. 4, 2026, p. e241, https://doi.org/10.1016/S2352-3026(26)00011-6.